Recalled Medicines & supplements – Current GIS Alerts 2026
Found 700 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Debridat
Risk of the presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may cause gastrointestinal damage or other mechanical complications during use. Potential effects: mechanical injuries, complications, risk to health or life.
Debridat
Risk of a quality defect in the medicinal product Debridat, 7.87 mg/g, granules for oral suspension, due to the risk of the presence of a foreign body in the product. Potential effects: gastrointestinal injuries, complications, possible threat to the patient’s health or life.
Debridat
Risk of presence of a foreign body in the medicinal product Debridat (Trimebutinum), 7.87 mg/g, granules for oral suspension, which may expose the patient to mechanical damage of the gastrointestinal tract or other complications during use. Potential effects: injuries, complications, health risk.
Apra-swift
A printing inconsistency in the dose on one side of the outer packaging was found (15 mg stated incorrectly, it should be 30 mg). Potential effects: improper dosing, lack of treatment efficacy or adverse effects.
Raniberl Max
Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was detected, causing the batches to be deemed non-compliant with quality requirements and potentially hazardous to patients’ health or life. Potential effects: carcinogenic action, organ damage, general poisoning.
Lakcid forte
The test showed that the product sample does not comply with the specification regarding the CFU count of lactic acid bacteria (Lactobacillus rhamnosus), which may mean a lower content of live probiotic bacteria than declared. Potential effects: lack of treatment efficacy, possible worsening of symptoms, delay of therapy.
Lakcid forte
It was found that the product sample does not comply with the specification regarding the number of lactic acid bacteria CFU, which may lead to reduced therapeutic effectiveness of the probiotic preparation. Potential effects: reduced treatment effectiveness, lack of the expected probiotic effect.
NuTRIflex Omega plus
Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating a quality defect of a solution intended for intravenous infusion. Potential effects: lack of therapeutic efficacy, metabolic disturbances, complications during parenteral nutrition.
Flavamed
A possible increased level of impurity E was identified in batches manufactured using glass bottles from one of the suppliers, which constitutes a quality defect of the medicinal product. Potential effects: possible adverse reactions or reduced treatment safety.
NuTRIflex Omega special
Cases of product discoloration were found, possibly accompanied by phase separation of the emulsion, indicating potential instability of the intravenously administered preparation. Potential effects: lack of treatment efficacy, infusion-related complications, adverse reactions.
Flavamed
Tests by the National Medicines Institute confirmed that the sample of Flavamed batch 82014 did not meet purity specification requirements due to an exceeded level of impurity E, which makes a potential health risk for patients plausible. Potential effects: possible adverse reactions, complications, reduced treatment safety.
Ranimax Teva
In connection with information from the Rapid Alert system on detection of N-nitrosodimethylamine (NDMA) contamination in products containing ranitidine and the substantiated potential risk to patients’ health or life. Potential effects: long-term exposure to NDMA, possible carcinogenic action and other serious toxic effects.
Ranigast Pro
Contamination of the active substance Ranitidinum with N-nitrosodimethylamine (NDMA) was detected, representing a quality defect of the product and potentially endangering patients’ health or life. Potential effects: poisoning, carcinogenic effects, serious health complications.
Ranigast
The presence of N-nitrosodimethylamine (NDMA) contamination was confirmed in the active substance ranitidine used to manufacture batches of Ranigast 0.5 mg/ml, solution for infusion, which may pose a potential risk to patients' health. Potencjalne skutki: increased risk of adverse effects, including possible carcinogenic action with long-term exposure.
Ranigast
The presence of N-nitrosodimethylamine (NDMA) contamination was found in the active substance ranitidine used to manufacture the Ranigast 150 mg, film-coated tablet batches, which constitutes a quality defect of the medicinal product. Potential effects: increased risk of carcinogenic effects and toxic liver damage.
Ranigast Fast
contamination with N-nitrosodimethylamine (NDMA) in the active substance Ranitidinum used to manufacture the concerned batches of Ranigast Fast. Potential effects: possible carcinogenic effects and other adverse effects related to toxic contamination.
Ranigast Max
Contamination of the active substance ranitidine with N-nitrosodimethylamine (NDMA) was found in batches of the medicinal product Ranigast Max, meaning the quality requirements are not met. Potential effects: possible toxic effects, including long-term health risks.
Mitomycin C Kyowa
Deviations were identified in the manufacturing process of the active substance, so it cannot be ensured that the products meet sterility specification requirements, which may pose a real threat to patients' health or life. Potential effects: infection, complications after intravenous administration, life‑threatening conditions.
Mitomycin C Kyowa
Due to identified deviations in the manufacturing process of the active substance, it cannot be ensured that the medicinal products made from it meet sterility specification requirements. The authority points to a potential direct threat to patients’ health or life. Potential effects: infection, severe post-injection complications, risk to health or life.
Clopidogrel Genoptim
A result outside the quality specification was found for the parameters: clopidogrel-related substances — impurity A and enantiomeric purity — impurity C, which may affect the safety and efficacy of the medicine. Potential effects: lack of treatment efficacy or adverse reactions.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.